Evidence map›Paper›PMID 31475007›Full record

ArticleFrontiers in immunology2019

Antibodies to Human Herpesviruses in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients.

Jonas Blomberg, Muhammad Rizwan, Agnes Böhlin-Wiener, Amal Elfaitouri, Per Julin, Olof Zachrisson, Anders Rosén, Carl-Gerhard Gottfries

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Recent research in myalgic encephalomyelitis/chronic fatigue syndrome: an evidence map.Health technology assessment (Winchester, England) · 2025
    Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Jonas BlombergSection of Clinical Microbiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Muhammad RizwanSection of Clinical Microbiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Agnes Böhlin-WienerSection of Clinical Microbiology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Amal ElfaitouriDepartment of Infectious Disease and Tropical Medicine, Faculty of Public Health, Benghazi University, Benghazi, Libya.
Per JulinNeurological Rehabilitation Clinic, Stora Sköndal, Sköndal, Sweden.
Olof ZachrissonGottfries Clinic AB, Mölndal, Sweden.
Anders RosénDivision of Cell Biology, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
Carl-Gerhard GottfriesGottfries Clinic AB, Mölndal, Sweden.
Uppsala University · SEKarolinska Institutet · SELinköping University · SEUniversity of Benghazi · LY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myalgic encephalomyelitis, also referred to as chronic fatigue syndrome (ME/CFS) is a debilitating disease characterized by myalgia and a sometimes severe limitation of physical activity and cognition. It is exacerbated by physical and mental activity. Its cause is unknown, but frequently starts with an infection. The eliciting infection (commonly infectious mononucleosis or an upper respiratory infection) can be more or less well diagnosed. Among the human herpesviruses (HHV-1-8), HHV-4 (Epstein-Barr virus; EBV), HHV-6 (including HHV-6A and HHV-6B), and HHV-7, have been implicated in the pathogenesis of ME/CFS. It was therefore logical to search for serological evidence of past herpesvirus infection/reactivation in several cohorts of ME/CFS patients (all diagnosed using the Canada criteria). Control samples were from Swedish blood donors. We used whole purified virus, recombinant proteins, and synthetic peptides as antigens in a suspension multiplex immunoassay (SMIA) for immunoglobulin G (IgG). The study on herpesviral peptides based on antigenicity with human sera yielded novel epitope information. Overall, IgG anti-herpes-viral reactivities of ME/CFS patients and controls did not show significant differences. However, the high precision and internally controlled format allowed us to observe minor relative differences between antibody reactivities of some herpesviral antigens in ME/CFS versus controls. ME/CFS samples reacted somewhat differently from controls with whole virus HHV-1 antigens and recombinant EBV EBNA6 and EA antigens. We conclude that ME/CFS samples had similar levels of IgG reactivity as blood donor samples with HHV-1-7 antigens. The subtle serological differences should not be over-interpreted, but they may indicate that the immune system of some ME/CFS patients interact with the ubiquitous herpesviruses in a way different from that of healthy controls.

Indexed as

AdultAntibodies, ViralCohort StudiesFatigue Syndrome, ChronicFemaleHerpesviridaeHerpesviridae InfectionsHerpesvirus 4, HumanHerpesvirus 6, HumanHost-Pathogen InteractionsHumansImmunoassayImmunoglobulin GMaleMiddle AgedAntibodies, ViralImmunoglobulin Ganti-herpesviral antibodiesEBVEpstein-Barr virusHHVhuman herpesvirusesME/CFSmyalgic encephalomyelitissuspension multiplex immunoassay

Identifiers

PMID31475007
PMCPMC6702656
OpenAlexW2965518944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.